Latest SEC Filings — Page 25
Most recent SEC EDGAR filings across all covered tickers, sorted chronologically. Wiseek AI reads each filing and scores it 1–10 for market-moving potential; click through for full analysis.
BGIN Blockchain Confirms 77.7% Revenue Plunge, $177M Net Loss for 2025 Amid Crypto Downturn and New Class Action Lawsuits
Onconetix Registers 25 Million Shares for Highly Dilutive ELOC Resale to Fund Operations and Merger
Rambus Discloses DOJ Criminal Antitrust Probe Alongside Mixed Q1 Results
EVCM filing
VLRS filing
TARA filing
VC filing
Amended 10-K Reveals Significant Related-Party Property Acquisitions and Executive Compensation Details
HAFC filing
Merchants Bancorp Reports Strong Q1 Results, Regulatory MOU Terminated
Shareholders to Vote on Equity Plans with Significant Potential Dilution
Arcellx Completes Acquisition by Gilead Sciences, Initiates Nasdaq Delisting
4D Molecular Therapeutics Details Executive Changes, Related-Party Deal, and Significant Potential Dilution in Proxy Filing
UMB Financial Reports Strong Q1 Earnings Beat, Raises Dividend, and Boosts Share Repurchase Program
Annual Report Reveals Unremediated Material Weakness, Significant Mexico Tax Hike, and License Revocation Risk Amidst Net Income Decline
Solaris Energy Secures Major 10-Year, 600+ MW Power Capacity Agreement
CareDx Reports Strong Q1, Raises Guidance, Acquires Naveris for up to $260M, and Authorizes $100M Buyback
ENVA filing
CLIR filing
Faraday Future Seeks Shareholder Approval for Massive Dilution, Reverse Split, and Incentive Plan Amid Delisting Threat
Shareholders to Vote on 50% Increase in Authorized Stock, Enabling Significant Future Capital Raises
ALEC filing
FLXS filing
U.S. GoldMining Extends Warrant Expiration Date Again to May 11, 2026
Robinhood Misses Q1 Revenue Estimates Despite Strong User Growth and Share Repurchases
Arrive AI Inc. Regains Nasdaq Compliance, Averting Delisting Threat
K Wave Media Clarifies Worldwide Distribution Deal with HYBE for K-Pop Concert Content
BLD filing
PepGen Details Executive Option Repricing and Significant Potential Dilution in Proxy Filing
Bolt Biotherapeutics Schedules Annual Meeting, Discloses High Executive Compensation and Governance Lapses Amidst Going Concern